ArticleBMC microbiology2026
ZnO@Carvacrol nanoparticles effectively suppress biofilm and quorum-sensing mechanisms in MDR Acinetobacter baumannii.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- In Vitro Synergistic Effects of Selected Essential Oil Components Against ClinicalMolecules (Basel, Switzerland) · 2026Article
- Carvacrol Modulates Tetracycline Susceptibility and Resistance Gene Expression in Multidrug-ResistantAnimals : an open access journal from MDPI · 2026Article
- Linalool exhibits potent antibacterial and anti-biofilm activity against carbapenem-resistant Acinetobacter baumannii.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultidrug-resistant (MDR) Acinetobacter baumannii (A. baumannii) is a serious public health concern. This is mainly due to its strong biofilm formation and quorum-sensing (QS) systems, which contribute to increased antibiotic resistance. This study aimed to evaluate the inhibitory effects of zinc oxide-carvacrol nanoparticles (ZnO@Carvacrol NPs) on biofilm formation and QS gene expression in MDR A. baumannii isolates.
methodsZnO@Carvacrol NPs were synthesized using a green technique and characterized by Fourier-transform infrared spectroscopy, scanning electron microscopy, X-ray diffraction, and energy-dispersive X-ray spectroscopy. Clinical isolates of A. baumannii were identified and tested for antimicrobial susceptibility. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of carvacrol and ZnO@Carvacrol NPs were determined. Biofilm formation ability was assessed using the crystal violet microtiter assay. Minimum biofilm inhibitory concentration (MBIC) and minimum biofilm eradication concentration (MBEC) were determined. The expression of biofilm- and QS–related genes, including bap, abaI, and abaR, in four clinical isolates and the ATCC BAA-747 was analyzed using qRT-PCR.
resultsThe synthesized nanoparticles featured a ZnO wurtzite crystal core, surface functional groups associated with carvacrol, and a nanoscale agglomerated morphology (50–100 nm). ZnO@Carvacrol NPs showed a high carbon content, with signals for zinc and oxygen, thereby confirming the successful production and surface modification. ZnO@Carvacrol NPs, with MIC and MBC values of 1.6 mg/mL, demonstrated greater effectiveness in inhibiting A. baumannii than carvacrol alone (MIC = 3.2 mg/mL and MBC = 6.4 mg/mL). ZnO@Carvacrol NPs decreased biofilm biomass (MBIC = 0.2 mg/mL and MBEC = 0.4 mg/mL), whereas carvacrol showed MBIC and MBEC values of 0.8 and 1.6 mg/mL, respectively. Carvacrol reduced abaI expression by 50%, while ZnO@Carvacrol decreased it by approximately 70% (P < 0.01). abaR expression decreased by 40% with carvacrol and 70% with ZnO@Carvacrol NPs (P < 0.01). The bap gene showed a 60% reduction with carvacrol and an 80% reduction with ZnO@Carvacrol NPs (P < 0.001).
conclusionThe anti-biofilm and anti-QS properties of ZnO@Carvacrol NPs against MDR A. baumannii showed promise. These findings suggest that ZnO@Carvacrol NPs have the potential to serve as an adjuvant in combating antibiotic resistance in A. baumannii.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.